Clinical Research Directory

Inclusion Criteria: * Woman aged 45 to 60 years (both inclusive). * Perimenopausal or postmenopausal status according to the Stages of Reproductive Aging Workshop +10 (STRAW+10) criteria. * Moderate to severe menopausal symptoms, defined as a total Menopause Rating Scale (MRS) score of 15 or higher at the baseline assessment prior to randomization. * Not receiving menopausal hormone therapy (MHT) and not having received it in the previous 3 months. * Ability to understand and complete the study questionnaires autonomously. * Written informed consent. Exclusion Criteria: * Known allergy or hypersensitivity to soy or any of its derivatives. * Known allergy or hypersensitivity to hops or to other species of the Cannabaceae family. * Personal history of breast cancer, endometrial cancer or any other hormone-dependent tumor. * Genital bleeding of undiagnosed cause. * Current use, or use in the previous 3 months, of MHT, tibolone, selective estrogen receptor modulators, or dietary supplements or products specifically intended for menopausal symptoms or with a relevant phytoestrogen content, or anticipated need to start any of them during the study. * Current treatment with antidepressants, anxiolytics, hypnotics, gabapentin or pregabalin. * Known liver disease or abnormal baseline liver profile (transaminases more than twice the upper limit of normal). * Moderate or severe renal insufficiency. * History of venous thromboembolic disease. * Oral anticoagulant treatment. * Body mass index (BMI) of 35 kg/m2 or higher. * Pacemaker or any other implantable electronic device (contraindication for bioimpedance). * Unstabilized major psychiatric disorder. * Risky alcohol consumption or substance dependence. * Simultaneous participation in another clinical trial or intervention study, or participation in one within the previous 30 days. * Pregnancy or lactation.